Fusion Antibodies (FAB) Competitors GBX 6.60 +0.05 (+0.76%) As of 04/17/2025 11:43 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesBuy This Stock FAB vs. OKYO, SAR, AOR, OPTI, AREC, RLM, POLB, NSCI, IMM, and SNGShould you be buying Fusion Antibodies stock or one of its competitors? The main competitors of Fusion Antibodies include OKYO Pharma (OKYO), Sareum (SAR), AorTech International (AOR), OptiBiotix Health (OPTI), Arecor Therapeutics (AREC), Realm Therapeutics (RLM), Poolbeg Pharma (POLB), NetScientific (NSCI), ImmuPharma (IMM), and Synairgen (SNG). These companies are all part of the "biotechnology" industry. Fusion Antibodies vs. OKYO Pharma Sareum AorTech International OptiBiotix Health Arecor Therapeutics Realm Therapeutics Poolbeg Pharma NetScientific ImmuPharma Synairgen Fusion Antibodies (LON:FAB) and OKYO Pharma (LON:OKYO) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, media sentiment, valuation, dividends, profitability, community ranking, analyst recommendations, institutional ownership and risk. Is FAB or OKYO more profitable? OKYO Pharma has a net margin of 0.00% compared to Fusion Antibodies' net margin of -195.95%. Fusion Antibodies' return on equity of -137.11% beat OKYO Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Fusion Antibodies-195.95% -137.11% -63.78% OKYO Pharma N/A -397.13%-154.72% Does the media favor FAB or OKYO? In the previous week, Fusion Antibodies' average media sentiment score of 0.00 equaled OKYO Pharma'saverage media sentiment score. Company Overall Sentiment Fusion Antibodies Neutral OKYO Pharma Neutral Do insiders & institutionals hold more shares of FAB or OKYO? 21.0% of Fusion Antibodies shares are held by institutional investors. 11.4% of Fusion Antibodies shares are held by company insiders. Comparatively, 31.9% of OKYO Pharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Does the MarketBeat Community favor FAB or OKYO? Fusion Antibodies received 47 more outperform votes than OKYO Pharma when rated by MarketBeat users. Likewise, 68.35% of users gave Fusion Antibodies an outperform vote while only 63.64% of users gave OKYO Pharma an outperform vote. CompanyUnderperformOutperformFusion AntibodiesOutperform Votes5468.35% Underperform Votes2531.65% OKYO PharmaOutperform Votes763.64% Underperform Votes436.36% Which has more risk and volatility, FAB or OKYO? Fusion Antibodies has a beta of 0.49, suggesting that its stock price is 51% less volatile than the S&P 500. Comparatively, OKYO Pharma has a beta of -0.06, suggesting that its stock price is 106% less volatile than the S&P 500. Which has higher valuation & earnings, FAB or OKYO? Fusion Antibodies has higher revenue and earnings than OKYO Pharma. Fusion Antibodies is trading at a lower price-to-earnings ratio than OKYO Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioFusion Antibodies£2.09M2.96-£4.10M-£4.45-1.48OKYO PharmaN/AN/A-£6.70M-£0.01N/A SummaryFusion Antibodies beats OKYO Pharma on 9 of the 12 factors compared between the two stocks. Get Fusion Antibodies News Delivered to You Automatically Sign up to receive the latest news and ratings for FAB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FAB vs. The Competition Export to ExcelMetricFusion AntibodiesBiotechnology IndustryMedical SectorLON ExchangeMarket Cap£6.21M£120.88M£5.31B£2.52BDividend YieldN/A3.76%5.45%4.80%P/E Ratio-1.483.0521.94131.32Price / Sales2.964,157.44380.66235,334.67Price / Cash9.0213.0538.2528.39Price / Book1.8834.176.454.43Net Income-£4.10M-£91.72M£3.22B£5.89B7 Day Performance-2.94%1.39%0.74%1.32%1 Month Performance-1.49%-6.39%-9.66%-0.52%1 Year Performance76.00%84.27%11.81%22.48% Fusion Antibodies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FABFusion AntibodiesN/AGBX 6.60+0.8%N/A+76.0%£6.21M£2.09M-1.4848Gap UpOKYOOKYO PharmaN/AN/AN/AN/A£23.24MN/A-140.007Gap DownSARSareumN/AGBX 18-5.3%N/AN/A£22.49MN/A-4.263,211Gap UpAORAorTech InternationalN/AN/AN/AN/A£19.99M£539,000.00-33.383OPTIOptiBiotix HealthN/AGBX 18+2.9%N/A+2.8%£17.63M£590,009.23-5.701ARECArecor TherapeuticsN/AGBX 38.50+1.3%N/A-69.3%£14.54M£6.04M-1.3610Gap UpHigh Trading VolumeRLMRealm TherapeuticsN/AN/AN/AN/A£13.41M£501,919.00-0.66N/APOLBPoolbeg PharmaN/AGBX 2.54-4.2%N/A-74.5%£13.06MN/A0.0012Gap DownNSCINetScientificN/AN/AN/AN/A£12.81M£1.45M-486.3626IMMImmuPharmaN/AGBX 2.37-8.9%N/A+2.6%£10.07M£-71,310.29-4.1013Gap DownSNGSynairgenN/AGBX 0.93-2.6%N/A-86.3%£9.04MN/A-0.5634Gap Down Related Companies and Tools Related Companies OKYO Pharma Alternatives Sareum Alternatives AorTech International Alternatives OptiBiotix Health Alternatives Arecor Therapeutics Alternatives Realm Therapeutics Alternatives Poolbeg Pharma Alternatives NetScientific Alternatives ImmuPharma Alternatives Synairgen Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (LON:FAB) was last updated on 4/21/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fusion Antibodies plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Fusion Antibodies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy FAB Stock Free FAB Stock Alerts